{
    "clinical_study": {
        "@rank": "87510", 
        "acronym": "ComorVIH", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the frequency of renal and bone toxicity in HIV\n      infected patients receiving antiretroviral therapy, and the outcome in terms of treatment\n      change or/and virological failure, in relation with the presence of classical factors, such\n      as diabetes or hypertension, the role of HIV itself, because of chronic inflammation, and\n      the effects of antiretroviral medication."
        }, 
        "brief_title": "Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Toxicity", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "detailed_description": {
            "textblock": "This is a retrospective cohort study involving 300 patients to determine the frequency of\n      renal and bone comorbidities/toxicity in a large population of HIV-infected patients\n      receiving antiretroviral therapy, in order to establish the differential role of classical\n      factors, HIV infection, or antiretroviral therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed HIV infection\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Prior therapy with antineoplastic chemotherapy or chronic treatment with\n             corticosteroids\n\n          -  Previous chronic therapy with antiresorptive bone therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HIV infected patients in active follow up, receiving antiretroviral therapy"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116751", 
            "org_study_id": "EC 039/14"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "HIV, antiretroviral, toxicity, eGFR, tubular involvement, BMD", 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "jcasado.hrc@gmail.com", 
                "last_name": "Jose L Casado, MD", 
                "phone": "34913368672"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28034"
                }, 
                "name": "Ramon y Cajal Hospital"
            }, 
            "investigator": {
                "last_name": "Jose L Casado, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients: Role of Classical Factors, HIV Infection, and Antiretroviral Therapy", 
        "other_outcome": {
            "description": "Evolution of renal and bone parameters in case of regimen discontinuation", 
            "measure": "Changes in renal and bone toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "2 years before entry"
        }, 
        "overall_contact": {
            "email": "jcasado.hrc@salud.madrid.org", 
            "last_name": "Jose L Casado, MD", 
            "phone": "34913368672"
        }, 
        "overall_official": {
            "affiliation": "Ramon y Cajal Hospital", 
            "last_name": "Jose L Casado, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number and percentage of patients with:\nConfirmed estimated glomerular filtration rate (eGFR) by CKD (chronic kidney disease)-epi equation decrease to < 60 ml/min, or/and\nMore than 25% of eGFR decrease during therapy, or/and\nTubular toxicity defined as at least two of confirmed proteinuria (> 300 mg/g), glycosuria with euglycemia, fractional excretion of urinary phosphate > 20%, or of uric acid > 10%. AND\nNumber and percentage of patients with bone mineral density (BMD) decrease > 10% during follow up or progression to osteopenia (from normal) or to osteoporosis (from osteopenia)", 
            "measure": "Incidence of Renal and Bone toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be evaluated for 2 years before"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116751"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Percentage of patients with regimen discontinuation (any drug in the regimen) because of renal or/and bone toxicity", 
            "measure": "Consequences of renal or bone toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be evaluated for 2 years before"
        }, 
        "source": "Asociacion para el Estudio de las Enfermedades Infecciosas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asociacion para el Estudio de las Enfermedades Infecciosas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}